anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study will be a randomized trial, with two intervention arms: 1) Aerobic training (AT) and 2) Combined training (CT) groups. The planned training period will be 12 weeks for each group. Patients of both groups will be asked to exercise three times a week. Each session will last 80 minutes for each group. Population: We will includ 60 male subjects ≥ 45 years old, with established diagnosis of hypertension (of at least one year), treated with pharmacological therapy and with resting BP values under acceptable control (systolic BP \<150 mmHg; diastolic BP \< 90 mmHg) at admission. All groups of anti-hypertensive drugs will be admitted; there will be no restriction on the number of anti-hypertensive drugs taken by the patients. Sustained BP increase during the exercise protocol will be managed with the administration of furosemide (25-50 mg/daily). Patients who will need further pharmacological interventions for lowering BP will be withdrawn from the study. The following exclusion criteria will be adopted: secondary hypertension; significant heart valve diseases; signs and or symptoms of myocardial ischemia during ergometric test; neurological and or orthopedic conditions contraindicating or limiting ET; significant COPD (FEV1 \<50%), or symptomatic peripheral arterial occlusive disease. Patients will be randomly assigned on 1:1 basis to either AT or CT group. The randomization code will be developed with a computer random-number generator to select random permuted blocks.

Exercise training protocols: AT group: every exercise session will include 10 min of warm-up, cool-down and flexibility exercises and 60 min of aerobic exercise with cycling and treadmill at 60-70% of VO2 peak.

CT group: patients will perform aerobic and resistance exercises in the same session. In order to balance the total amount of exercise, exercise sessions of the CT group will be organized as follow: 40 minutes of aerobic training with cycling and treadmill at 60-70% of VO2 peak; 20 minutes of resistance training including the following exercises: leg press and extension, shoulder press, chest press, low row and vertical traction. all the subjects Each strength exercise will be performed by patients at 60% of their maximal voluntary contraction. Patients of CT group will performed also 10 min of warm-up, cool-down and flexibility exercises. The one maximum repetition test (1RM) will be used to determine the RE load.
PURPOSE: An obesity therapeutic agent using black soybean fermentation is provided to manufacture a functional food and a drug. CONSTITUTION: An obesity therapeutic agent contains daidzin of chemical formula 1 as an active ingredient, which is prepared by inoculating black soybeans with a Monascus sp. culture medium, fermenting, and extracting. The obesity therapeutic agent contains genistin of chemical formula 2, which is prepared by inoculating black soybeans with a Monascus sp. culture medium, fermenting, and extracting. Monascus sp. is selected among M.purpureus, M. pilosus, M. ruber, and M. kaoliang.
Celecoxib capsule is a nonsteroidal anti-inflammatory drug, available as capsules containing 50 mg, 100 mg, 200 mg and 400 mg celecoxib for oral administration. The chemical name is 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl-substituted pyrazole. The molecular weight is 381.38. Its molecular formula is C17H14F3N3O2S, and it has the following chemical structure:

Celecoxib is a white or almost white, crystalline powder with a pKa of 11. Celecoxib is freely soluble in ethanol, soluble in methylene chloride, practically insoluble in water.

The inactive ingredients in Celecoxib include: croscarmellose sodium, lactose monohydrate DCL 11, magnesium stearate, povidone (K 30) and sodium lauryl sulfate.

The capsule shells contain gelatin, sodium lauryl sulfate and titanium dioxide. In addition, 50 mg capsule shell contain iron oxide red, 100mg capsule shell contain FD&C blue 1 and FD&C red 40, 200mg capsule shell contain iron oxide yellow and 400mg capsule shell contain FD&C blue 2 and iron oxide yellow.

The imprinting ink contains iron oxide black, propylene glycol, potassium hydroxide, povidone, shellac, sodium hydroxide and titanium dioxide.
In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
The invention discloses a rivastigmine containing external patch and a preparation process thereof. The external patch is formed by uniform mixing of the following components by weight: 100 parts of rivastigmine, 10-50 parts of poloxamer, 300-800 parts of water, and 800-1500 parts of a water emulsion type polyacrylate pressure sensitive adhesive. The specific preparation process includes: dissolving rivastigmine and poloxamer in water, then adding the water emulsion type polyacrylate pressure sensitive adhesive, and mixing the materials evenly, coating an anti-sticking layer with the drug-adhesive mixed solution evenly, performing heating drying at 40DEG C-70DEG C, and conducting compounding with a backing film; and carrying out slitting, die cutting and packaging, thus obtaining the external patch. The rivastigmine containing external patch provided by the invention performs transdermal drug delivery, releases drug evenly, and has mild and lasting effect. The preparation process provided by the invention is simple, reduces the production cost, and does not generate environmental pollution. Also, the rivastigmine containing external patch has the advantages of strong adhesion, no irritation to skin, no redness and swelling or itching phenomenon, good patient compliance, and convenient use and carrying.
Solution: Instill one or two drops into the conjunctival sac(s) of the affected eye(s) every two to three hours initially. Dosages may be tapered by increasing the time interval between doses as the condition responds. The usual duration of treatment is seven to ten days.

Ointment: Apply a small amount (approximately one-half inch ribbon) into the conjunctival sac(s) of the affected eye(s) every three to four hours and at bedtime. Dosages may be tapered by increasing the time interval between doses as the condition responds. The ointment may be used as adjunct to the solution. The usual duration of treatment is seven to ten days.

How to apply CETAMIDE™ Ointment:

  1. Tilt your head back.
  2. Place a finger on your cheek just under your eye and gently pull down until a “V” pocket is formed between your eyeball and your lower lid.
  3. Place a small amount (about ½ inch) of CETAMIDE™ Ointment in the “V” pocket. Do not let the tip of the tube touch your eye.
  4. Look downward before closing your eye.
Preeclampsia (PE) is a serious complication of third trimester pregnancy manifested by high blood pressure, proteinuria, edema, encephalopathy sometimes with seizures, and hepatic failure. There is no known specific treatment, although palliative measures such as antihypertensive drugs, magnesium, steroids and early delivery improve outcomes. Multiple abnormalities have been demonstrated in PE but the relation of these abnormalities to the cause, pathophysiology and treatment is unknown. One of these abnormalities is elevation in the circulating level of a "digoxin-like" factor (EDLF), an unknown substance that cross reacts with digoxin antibodies and inhibits Na,K ATPase. An extensive literature supports the hypothesis that increased levels of EDLF may be a causative factor in the pathogenesis of hypertension. Increased levels of this factor are found both in maternal and fetal blood, both in normal pregnancy, and in pregnancy complicated by PE. Levels of this factor are higher in PE than in normal pregnancy suggesting it might play a role in the pathophysiology of PE.

Digibind (Glaxo Smith Kline) is a commercially available FAB fragment, antidigoxin antibody approved for the treatment of digoxin intoxication. In experimental models of hypertension with elevated EDLF levels, Digibind has been shown to lower blood pressure, suggesting that the antibody cross reacts with EDLF. These observations have led to the hypothesis that Digibind might ameliorate some of the manifestations of PE, especially the hypertension. Based on an extensive pre-clinical literature supporting that hypothesis, and encouraging results in 8 cases, a clinical trial is planned to test the effect of Digibind in severe PE. The study is a multi- site, parallel, double blind, placebo controlled, randomized trial. After randomization, 50 patients will be given the usual treatment for severe PE, plus study drug (Digibind or placebo) every six hours, for 48 hours. The study may be terminated during the treatment period for standard indications for early delivery.

Data collection will include: delivery latency, maternal blood pressure, antihypertensive use, renal function, hepatic function, CBC and platelet count, and umbilical artery blood flow by color doppler. Standard maternal and fetal monitoring will be followed. Newborn assessment will include: status at birth, APGAR score, NICU length of stay, respirator use and duration, and any medical complications. Adverse events will be recorded.
The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
The invention relates to a tumour-relative gene and its use. The invention determines the relativity of one human serum prohibition relative gene (Si-1) and the tumour. It is in the long arm of human 2-chromosome, the whole length accounting for about 45Kb DNA sequence, duplicating product (cDNA sequence) 5249bp, code 791 amino acid containing 21 exons, and code sequence containing 19 exons. It is expressed in the growth-stopping or differential cells, and if too strongly expressed, can prohibit the growth of tumour cell. By detecting its structure in the tumour tissue, we find that the sum of its deletion or mutation rate reaches 35%. The research result shows that: it can be applied to diagnostic sign gene for multiple tumours, and also be used as the target gene for the tumour gene therapy.
PROBLEM TO BE SOLVED: To obtain the subject agent useful for treating diseases caused by the increase of a lipoperoxide in vivo such as nephropathia by including a specified curcumin derivative and/or a specified tetrahydro curcumin derivative. SOLUTION: This prophylactic or therapeutic agent is obtained by including a curcumin derivative of formula I (R<1> to R<4> are each H, hydroxy or a lower alkoxy) [e.g. diferuloylmethane or (E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6- heptadiene-3,5-dionel and/or a tetrahydro curcumin derivative of formula II as active ingredient(s) and preferably furthermore a support (e.g. a diluent, a vehicle). The daily dose of the curcumin and/or tetrahydro curcumin is preferably 1 mg to 2 g per kg-body weight. The compounding ratio (by weight) of the active ingredient(s) is preferably 1-99.0% based on 100% whole compositions of the preparation.
The invention discloses a method processing fleece-flower root by simultaneously combining prepared rehmannia root and prepared rehmannia root juice and relates to the field of traditional Chinese medicinal materials. The method processing fleece-flower root by simultaneously combining prepared rehmannia root and prepared rehmannia root juice utilizes juice from prepared rehmannia root steaming to steam 'prepared rehmannia root liquid manufactured fleece-flower root', achieves steaming effect of two kinds of medicines, saves rehmannia root medicinal resource waste during prepared rehmannia root juice manufacture, and saves time, labor and energy. The method comprises the steps of directly letting steam in, mixing yellow rice or millet wine with the fleece-flower root, placing the fleece-flower root on a lower layer of a steaming container, and steaming the fleece-flower root through prepared rehmannia root juice flowed from an upper layer rehmannia root mixed with the yellow rice or millet wine. Finally, steamed fleece-flower root can not only achieve processing with wine, but also achieves processing with prepared rehmannia root juice; the appearance is black, and the effect of even and consistent inside and outside. Simultaneously, rehmannia root achieves the effect of steaming with wine, the black is like lacquer, the sweetness is like candy, the operation is practicable, and time, labor and energy are saved. Steamed fleece-flower root and rehmannia root are good in color and high in yield and can both achieve requirements of traditional processing.
BACKGROUND: The optima preoperative biliary drainage before pancreaticoduodenectomy in patients with biliary tract and pancreatic cancer remains controversial.
METHODS: A total of 898 patients who underwent preoperative biliary drainage via endoscopic retrograde biliary drainage, endoscopic transnasal biliary drainage, or percutaneous transhepatic biliary drainage before pancreaticoduodenectomy for biliary tract and pancreatic cancer were included. Perioperative and long-term outcomes were analyzed.
RESULTS: The Clavien-Dindo grade ≥3 morbidity rates after pancreaticoduodenectomy were higher in the endoscopic retrograde biliary drainage (21.9%; P = .001) or endoscopic transnasal biliary drainage (20.2%; P = .007) than in the percutaneous transhepatic biliary drainage (9.7%) groups. In biliary tract cancer, the frequency of dissemination after pancreaticoduodenectomy was higher in the percutaneous transhepatic biliary drainage (15.3%) than in the endoscopic retrograde biliary drainage (0.7%; P = .001) and endoscopic transnasal biliary drainage (4.1%; P = .037) groups; percutaneous transhepatic biliary drainage was an independent factor associated with worse disease-free survival (P = .04), whereas in pancreatic cancer the frequency of dissemination and survival was comparable among the 3 preoperative biliary drainage methods. Albumin <3.9 g/dL was independently associated with worse overall survival in patients with both pancreatic (P = .038) and biliary tract (P = .002) cancers, respectively. During biliary drainage, external drainage (P = .038) was independently associated with albumin <3.9 g/dL; albumin was higher in endoscopic retrograde biliary drainage group than in endoscopic transnasal biliary drainage or percutaneous transhepatic biliary drainage groups after 21 days from tube insertion.
CONCLUSION: In biliary tract cancer, percutaneous transhepatic biliary drainage may carry the risk of increasing the incidence of disseminative recurrence. In pancreatic cancer, percutaneous transhepatic biliary drainage is preferable owing to fewer complications without influencing recurrence. However, if patients cannot undergo surgery immediately, endoscopic retrograde biliary drainage will be applicable to help the preservation of nutritional status, which can have an impact on survival.
Cancer cells are treated by encapsulating a tumour specific material (I) (esp. an antibody or radioisotope) with a material (II) that can be removed on entering a cancer cell after a preselected time, to produce a total particle size 1 mu. the intravenously injecting the encapsulated particles and removing (II) in situ so that (I) is released in the cancer cells. Cancer cells are killed selectively without harmful effects on normal cells, wherever the cancer cells are located in the patient; cells detached from the tumour and a drift in the vascular system or lymphatic system are also killed. In an example Ga citrate (gallium-67) in saline was admin. to a subject at 0.02-0.1 mC./kg. After 12 hrs. the subject was placed in a large induction coil and treated electromagnetically.
After instillation of topical benoxinate hydrochloride 0.4%, subconjunctival injection of 2% lidocaine was done beneath the lower punctum, then Nettleship dilator was used to dilate the punctum. A single blade of a small Westcott spring scissor or Vannus scissor is placed within the ampulla of the lacrimal canaliculus, with the remaining blade placed on the conjunctival surface of the posterior aspect of the eyelid. The first vertical snip is made at the vertical canaliculus. The second vertical snip is made from the edge of the first snip to create a flap. The final horizontal snip was made at the base. The triangular flap is removed and three sutures are placed, in an interrupted manner, at the posterior wall of the ampulla using 10-0 nylon. Hemostasis was done by compression with a cotton tip for one minute until bleeding stop. The sutures are removed 1 week after the surgery.
PURPOSE:To produce the titled substance useful as an antineoplastic agent, on an industrial scale, by extracting the bark of Melia azadirachta with hot water, purifying the extract, treating with boric acid, concentrating by strongly basic anion exchange chromatography and cation exchange chromatography, and freeze-drying the product. CONSTITUTION:The bark of Melia azadirachta is extracted with hot water, purified, and treated with boric acid or its salt to obtain a boric acid complex compound. The complex compound is adsorbed to a strongly basic anion exchange material, and eluted with a boric acid buffer solution. The eluted solution is deionized with a cation exchange resin, the boric acid is converted to methyl ester with an alcohol and removed from the system by vacuum distillation, and the residue is freeze-dried to obtain the objective polysaccharide N9GI having the following characteristics. Appearance, white-pale yellowish brown powder; solubility, soluble in water and insoluble in methanol, acetone, etc.; color reaction, positive to phenol-sulfuric acid reaction, etc. The substance can be produced on large scale with simple operation.
The present disclosure provides compositions, for use in a method of preferential delivery of a therapeutic agent to a non-liver organ or non-liver cell in a subject, comprising: the therapeutic agent; and a lipid nanoparticle comprising: (1) a selective organ targeting (SORT) compound; (2) an ionisable cationic lipid; (3) and optionally, a phospholipid; wherein the composition delivers a greater amount of, or provides a greater amount of activity of, the therapeutic agent in the non-liver organ or cell in the subject compared to that achieved absent the SORT lipid. The compositions may also comprise a polyethylene glycol-conjugated (PEGylated) lipid (e.g. DMG-PEG) and also optionally a steroid, preferably cholesterol. The non-liver organ is preferably the lung(s), the liver, the lymph node(s), or the spleen. The therapeutic agent may comprise a nucleic acid. The SORT compound is preferably a permanently cationic lipid comprising a quaternary ammonium ion (e.g. DOTAP, 1,2-Dioleoyl-3-trimethylammonium propane), a permanently anionic lipid comprising a phosphate group or a zwitterionic C6-24diacyl phosphatidylcholine (e.g. DSPC). The ionisable cationic lipid preferably comprises an ammonium group which is positively charged at physiological pH and contains at least two hydrophobic groups (e.g. 5A2-SC8). It may be a dendron or dendrimer.
Resistance exercise, paired with protein ingestion, leads to the accretion of muscle proteins that over time results in the augmentation of muscle size and muscle strength. By virtue of its ability to stimulate increases in muscle size and strength, resistance exercise is an effective method that can be used by healthcare practitioners to promote the recovery of lost muscle mass resulting from a period of immobilization (resulting from broken bones, elective surgery, etc.). However, while exercise in general is an effective therapeutic strategy to combat muscle loss and frailty, the extent to which individuals respond to resistance exercise is highly variable. Some individuals exhibit large changes in muscle size (high responders) whereas other exhibit little to no change (low responders). Thus, where as one resistance exercise program might be an appropriate treatment for one individual following disuse, another individual might require a greater stimulus and/or pharmaceutical assistance in order to fully recover. What is currently unknown is whether individuals who experience the most profound increases in skeletal muscle mass following resistance exercise also lose the most muscle upon limb immobilization. Answering this gap in our knowledge will be the primary goal of this study. The procurement of this knowledge will hopefully permit the development of individualized exercise programs that can be used to influence the recovery of skeletal muscle that is lost with inactivity and immobilization.
ZELAPAR Orally Disintegrating Tablets are available containing 1.25 mg selegiline hydrochloride in a Zydis® formulation. Each pale yellow tablet is imprinted with a stylized “V”. Ten tablets in a blister card are provided in a sachet pouch. The sachet pouch is stored inside a clear child-resistant outer pouch and is packaged in a carton. The blister card and sachet pouch are not child-resistant. The clear outer pouch is child-resistant.

ZELAPAR (selegiline hydrochloride) is available as:

    NDC 0187-0453-02 1.25 mg per tablet carton of 6 sachet pouches (60 tablets)

Store at controlled room temperature, 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Use within 3 months of opening pouch and immediately upon opening individual blister. Store blister tablets in sachet pouch at all times. Keep sachet pouch sealed or closed inside clear child-resistant pouch provided. Potency cannot be guaranteed after 3 months of opening the sachet pouch.
An apparatus includes a network interface and a processor. The network interface is configured to communicate over a communication network. The processor is 5 configured to receive (i) data, including a medical parameter acquired as a function of time, and (ii) a selection of one or more time intervals of interest within the time period. The processor is further configured to compress a first portion of the data, which is within the 10 selected time intervals, at a first resolution, and compress a second portion of the data, which is outside the selected time intervals, at a second resolution, which is coarser than the first resolution. The processor is additionally configured to transmit the compressed first 15 and second portions of the data, via the network interface, over the communication network. 40" Low 44 50 High 44 Low resolution resolution resolution 100 68Server -- -- processor Local Remote processor processor ,36 42658 Interface522 Local display I 69 - ---- Remote display
The study is being done to examine the effects of a medication called mifepristone in children with Cushing's disease. Since a child's body may absorb and use mifepristone in a different way than adults, it is important to have information about the amount of mifepristone to give children and what will happen to it. Mifepristone has been FDA approved for use only in adults with Cushing's syndrome, and it is important to learn if mifepristone improves the symptoms and signs of Cushing's disease in children. The study is limited to children with Cushing's syndrome due to a pituitary tumor (Cushing's disease) and will not enroll children with Cushing's syndrome due to other causes. The study will investigate how children's bodies absorb and process mifepristone, how it works in children and what effect it has on the use of sugar in the body, on the child's weight and on growth hormone. An important part of the study is to evaluate the side effects of mifepristone in children.
Patients will be advised to take 4 liters of polyethylene glycol (PEG), split into two 2 liter doses. The first 2 liters are to be taken starting at 1800 hours the day before the colonoscopy, and the second dose is to be taken starting 4-5 hours prior to the scheduled time for the colonoscopy. Each dose will be taken within a 2-hour time span.